Literature DB >> 25040541

A systematic review and meta-regression analysis of mivacurium for tracheal intubation.

L E H Vanlinthout1, S H Mesfin, N Hens, B F Vanacker, E N Robertson, L H D J Booij.   

Abstract

We systematically reviewed factors associated with intubation conditions in randomised controlled trials of mivacurium, using random-effects meta-regression analysis. We included 29 studies of 1050 healthy participants. Four factors explained 72.9% of the variation in the probability of excellent intubation conditions: mivacurium dose, 24.4%; opioid use, 29.9%; time to intubation and age together, 18.6%. The odds ratio (95% CI) for excellent intubation was 3.14 (1.65-5.73) for doubling the mivacurium dose, 5.99 (2.14-15.18) for adding opioids to the intubation sequence, and 6.55 (6.01-7.74) for increasing the delay between mivacurium injection and airway insertion from 1 to 2 min in subjects aged 25 years and 2.17 (2.01-2.69) for subjects aged 70 years, p < 0.001 for all. We conclude that good conditions for tracheal intubation are more likely by delaying laryngoscopy after injecting a higher dose of mivacurium with an opioid, particularly in older people.
© 2014 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25040541     DOI: 10.1111/anae.12786

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  Comparative Analysis of the Anesthesia Effect of Cisatracurium Besylate and Mivacurium Chloride Otolaryngology Surgery.

Authors:  Shibin Huang; Qi Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-18       Impact factor: 2.650

2.  Comparison of 3 Rates for the Continuous Infusion of Mivacurium During Ambulatory Vitreoretinal Surgery Under General Anesthesia: A Prospective, Randomized, Controlled Clinical Trial.

Authors:  Yi Zhang; Chunhua Xi; Jianying Yue; Mengmeng Zhao; Guyan Wang
Journal:  Drug Des Devel Ther       Date:  2022-09-16       Impact factor: 4.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.